-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2025-522169-31-00
4
2025-10-30
Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
-
2023-506843-40-00
5
2025-10-29
Mycobacterium xenopi pulmonary infection
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2025-520694-39-00
4
2025-10-24
Metastatic or locally advanced irresectable (stage IV) gastric cancer
-
2023-508785-16-00
5
2025-10-17
Very preterm neonate (gestational age at birth < 32 WG) with corrected
-
2024-518358-17-00
4
2025-10-06
Squamous cell carcinoma of the esophagus
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-517633-40-00
5
2025-09-18
Hidradenitis Suppurativa
-
2024-513171-41-00
5
2025-09-11
Vitiligo
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-520395-99-00
7
2025-08-12
Advanced solid tumors
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2023-509788-25-00
6
2025-06-16
Rheumatoid arthritis
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-511720-13-00
5
2025-05-14
adnexal torsion
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2022-501315-13-00
5
2025-03-06
Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant